ArticleFrontiers in pharmacology2025
Correlation analysis between plasma concentration of nilotinib and clinical efficacy and safety in patients with chronic myeloid leukemia: a single-center retrospective cohort study.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Optimizing Flumatinib Therapy in Chinese Chronic-Phase Chronic Myeloid Leukemia Based on Therapeutic Drug Monitoring.Drug design, development and therapy · 2026Article
- Current and emerging drugs for Parkinson's disease: mechanisms, clinical evidence, and future directions.Frontiers in pharmacology · 2026Review
Corrections and comments
- Erratum issued
- Erratum issued
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to investigate the correlation between nilotinib plasma concentrations and clinical efficacy and safety in patients with chronic myeloid leukemia (CML), thereby supporting personalized therapeutic optimization. Methods: We conducted a retrospective cohort study of 121 CML patients receiving nilotinib with therapeutic drug monitoring (TDM) at Nanfang Hospital of Southern Medical University between March 2021 and February 2024. Major molecular response (MMR) and adverse events (CTCAE v5.0) were analyzed against concentrations. Receiver operating characteristic (ROC) curves defined thresholds; dose-normalized exposure (C Results: The effective group showed higher nilotinib concentrations than those in the ineffective group (1,036.40 ± 463.67 vs. 737.14 ± 518.97 ng mL Conclusion: Nilotinib concentrations predict MMR attainment independent of TDM-driven dose adjustments (validated via C
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.